Associated Papers
FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AML.
Pasupuleti SK et al.
Npj Precision Oncology, 2026
Clonal architecture of FLT3-ITD and acquired 13q uniparental disomy define prognostic heterogeneity and therapeutic vulnerabilities in acute myeloid leukemia.
Lai A et al.
Neoplasia (new York, N.y.), 2025
Unveiling splicing disruptions due to common somatic variants in acute myeloid leukemia.
Morote-Faubel M et al.
Human Genomics, 2025
Novel molecular mechanisms of FLT3 deregulation: from the acute myeloid leukemia experience to therapeutic insights in acute lymphoblastic leukemia.
Lo Schiavo F et al.
Molecular Cancer, 2025
Current Therapeutic Strategies for FLT3-Mutated Acute Myeloid Leukemia: A Narrative Review.
Swanson L et al.
Cureus, 2025
Persistent postremission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia.
Chow RD et al.
Blood Advances, 2025
Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challenges.
Rataj J et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2025
A structure-based tool to interpret the significance of kinase mutations in clinical next generation sequencing in cancer.
Rangarajan A et al.
Frontiers in Oncology, 2025
Understanding the characteristic behaviour of the wild-type and mutant structure of FLT3 protein by computational methods.
Younus S et al.
Computational and Structural Biotechnology Journal, 2025
Atypical Multifocal Granular Cell Tumor with FLT3 Y842C Somatic Mutation: A case report and a review of the literature.
Zara Rozalen A et al.
La Tunisie Medicale, 2024
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Early drivers of clonal hematopoiesis shape the evolutionary trajectories of de novo acute myeloid leukemia.
Chow RD et al.
Medrxiv : the Preprint Server for Health Sciences, 2024
Non-canonical FLT3 alterations reveal novel germline FLT3 variants leading to somatic gene rescue mutations.
Gordon J et al.
Blood Cancer Journal, 2024
Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia.
Hu C et al.
Cell Communication and Signaling : Ccs, 2024
Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML.
Macečková D et al.
Molecular Biology Reports, 2024
Landscape of FLT3 Variations Associated with Structural and Functional Impact on Acute Myeloid Leukemia: A Computational Study.
Mirza Z et al.
International Journal of Molecular Sciences, 2024
Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib.
Wang P et al.
Cancer Research, 2024
Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia.
Gutierrez-Camino A et al.
British Journal of Cancer, 2024
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML.
Popescu B et al.
Cell Reports. Medicine, 2023
Understanding the Role of Activation Loop Mutants in Drug Efficacy for FLT3-ITD.
Kazi JU et al.
Cancers, 2023
A Review of FLT3 Kinase Inhibitors in AML.
Negotei C et al.
Journal of Clinical Medicine, 2023
Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors.
Vodicska B et al.
World Journal of Pediatrics : Wjp, 2023
Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy.
Ge SS et al.
British Journal of Haematology, 2023
Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia.
Ezelarab HAA et al.
Bmc Chemistry, 2023
Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia.
Kotini AG et al.
Blood Cancer Discovery, 2023
How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia.
Haage TR et al.
Cancers, 2023
Resistance to a tyrosine kinase inhibitor mediated by changes to the conformation space of the kinase.
Freire TS et al.
Physical Chemistry Chemical Physics : Pccp, 2023
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn N et al.
Leukemia, 2022
Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia.
Isobe T et al.
Nature Communications, 2022
The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms.
Ferng TT et al.
Molecular Cancer Therapeutics, 2022
The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report.
He S et al.
The Journal of International Medical Research, 2022
SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data.
Medeiros JJF et al.
Bioinformatics (oxford, England), 2022
Developments and challenges of FLT3 inhibitors in acute myeloid leukemia.
Ge SS et al.
Frontiers in Oncology, 2022
In a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reported.
Anekpuritanang T et al.
Blood Advances, 2021
Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes.
Ferraro F et al.
Proceedings of the National Academy of Sciences of the United States of America, 2021
Transcriptional and Mutational Profiling of B-Other Acute Lymphoblastic Leukemia for Improved Diagnostics.
Chouvarine P et al.
Cancers, 2021